Day One Biopharma (DAWN) director’s options and RSUs cashed out at $21.50
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Day One Biopharmaceuticals director Garland J. Scott reported dispositions of equity awards to the company in connection with its cash merger with Servier. On April 23, 2026, 15,000 restricted stock units and several stock option grants covering 22,500, 32,335, 37,500, 28,700 and 48,072 shares of common stock were disposed of to the issuer.
Under the merger, each common share was purchased or converted into the right to receive $21.50 in cash per share. At the merger’s effective time, all stock options and RSUs, which had become fully vested immediately beforehand, were canceled and converted into cash equal to the $21.50 merger consideration, or for options the $21.50 amount minus the applicable exercise price, less taxes.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Garland J. Scott
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy Common Stock) | 48,072 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 28,700 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 37,500 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 32,335 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 22,500 | $0.00 | -- |
| Disposition | Restricted Stock Unit (RSU) | 15,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy Common Stock) — 0 shares (Direct, null);
Restricted Stock Unit (RSU) — 0 shares (Direct, null)
Footnotes (1)
- The options are fully vested. On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.
Key Figures
Merger cash price per share: $21.50 per share
RSUs disposed: 15,000 units
Option grant 1 shares: 22,500 shares
+3 more
6 metrics
Merger cash price per share
$21.50 per share
Cash consideration for each share of common stock in the merger
RSUs disposed
15,000 units
Restricted stock units canceled and converted to cash at merger
Option grant 1 shares
22,500 shares
Stock option (right to buy common stock) disposed to issuer
Option grant 1 exercise price
$7.01 per share
Conversion or exercise price for 22,500-share option grant
Option grant 2 shares
32,335 shares
Stock option disposed to issuer at merger closing
Option grants exercise price
$8.99 per share
Conversion or exercise price for several option grants
Key Terms
Restricted Stock Unit (RSU), Agreement and Plan of Merger, Merger Consideration, stock option, +1 more
5 terms
Restricted Stock Unit (RSU) financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share..."
A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.
Agreement and Plan of Merger financial
"entered into an Agreement and Plan of Merger (the "Merger Agreement")."
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Merger Consideration financial
"automatically converted into the right to receive the Offer Price (the "Merger Consideration"),"
Merger consideration is the total payment a company or buyer offers to shareholders of a target company in exchange for combining the two businesses, and can include cash, shares in the surviving company, debt assumption, or a mix of these. Investors care because the form and amount affect the deal’s value, tax consequences, immediate cash received versus future ownership, and the risk and upside of holding new shares — similar to choosing between cash now or stock that could grow later.
stock option financial
"At the effective time of the Merger, each stock option and restricted stock unit was canceled..."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Offer Price financial
"purchased for $21.50 per share (the "Offer Price"), net to the seller in cash,"
The offer price is the amount per share that a company or underwriter sets when selling new stock or bonds to investors, like the price tag on an item in a store. It matters because it determines how much investors must pay, shapes the initial market value of the security, and influences whether demand will be strong or weak — which affects early trading performance and potential returns.
FAQ
What did Day One Biopharmaceuticals (DAWN) director Garland J. Scott report on this Form 4?
Garland J. Scott reported dispositions of restricted stock units and stock options back to Day One Biopharmaceuticals. These transactions occurred when the company was acquired for cash, and his equity awards were canceled and converted into cash payments under the merger terms.
How many Day One Biopharmaceuticals RSUs were canceled in the merger for Garland J. Scott?
The Form 4 shows 15,000 restricted stock units were disposed of to the issuer. Each RSU represented one share of common stock, and at the merger’s effective time they were canceled and converted into a cash payment equal to the $21.50 per-share merger consideration.
What stock options of Garland J. Scott in Day One Biopharmaceuticals were affected by the Servier merger?
Scott’s affected stock options covered 22,500, 32,335, 37,500, 28,700 and 48,072 shares of Day One common stock. These fully vested options were canceled at the merger closing and converted into cash equal to $21.50 per share minus each option’s exercise price.
How were Day One Biopharmaceuticals RSUs structured before the merger for Garland J. Scott?
Each restricted stock unit represented a contingent right to receive one share of common stock for no consideration. RSUs were designed to vest on a specified future date or the 2026 annual stockholders’ meeting, after which shares would be delivered if service conditions were met.